Pfizer’s Hympavzi secures FDA expanded indications for haemophilia
Hympavzi is approved for routine prophylaxis to prevent bleeding episodes in US patients six years and above.
Drug Development
Sanofi and Owkin partner to develop next-generation biopharma AI agents
EC grants marketing authorisation for IntraBio’s Aqneursa
Pfizer signs licence agreement with Chai for AI drug discovery
Biogen’s salanersen gains FDA breakthrough therapy designation for SMA
Cellares and TScan to assess automated manufacturing of TSC-101 therapy
Regeneron and CytomX extend cancer therapy partnership to $4bn deal
AbbVie receives EC approval for Aquipta to treat migraine
